DE60032633D1 - Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung - Google Patents
Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendungInfo
- Publication number
- DE60032633D1 DE60032633D1 DE60032633T DE60032633T DE60032633D1 DE 60032633 D1 DE60032633 D1 DE 60032633D1 DE 60032633 T DE60032633 T DE 60032633T DE 60032633 T DE60032633 T DE 60032633T DE 60032633 D1 DE60032633 D1 DE 60032633D1
- Authority
- DE
- Germany
- Prior art keywords
- taxanes
- cytotoxic
- binding agent
- therapeutic use
- cell binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16722899P | 1999-11-24 | 1999-11-24 | |
US167228P | 1999-11-24 | ||
PCT/US2000/030149 WO2001038318A1 (en) | 1999-11-24 | 2000-11-21 | Cytotoxic agents comprising taxanes and their therapeutic use |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60032633D1 true DE60032633D1 (de) | 2007-02-08 |
DE60032633T2 DE60032633T2 (de) | 2007-10-04 |
Family
ID=22606479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60032633T Expired - Lifetime DE60032633T2 (de) | 1999-11-24 | 2000-11-21 | Zytotoxische mittel, die taxane enthalten und ihre therapeutische anwendung |
Country Status (13)
Country | Link |
---|---|
US (11) | US6340701B1 (de) |
EP (1) | EP1242401B1 (de) |
JP (1) | JP2003514903A (de) |
AT (1) | ATE349438T1 (de) |
AU (1) | AU765588C (de) |
CA (1) | CA2388063C (de) |
DE (1) | DE60032633T2 (de) |
DK (1) | DK1242401T3 (de) |
ES (1) | ES2276708T3 (de) |
HK (1) | HK1049997B (de) |
NZ (1) | NZ517772A (de) |
PT (1) | PT1242401E (de) |
WO (1) | WO2001038318A1 (de) |
Families Citing this family (165)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
JP4808846B2 (ja) * | 1999-02-24 | 2011-11-02 | ザ ユーエイビー リサーチ ファンデイション | 癌の標的付けられた治療のためのタキサン誘導体 |
WO2001024763A2 (en) | 1999-10-01 | 2001-04-12 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
ES2276708T3 (es) * | 1999-11-24 | 2007-07-01 | Immunogen, Inc. | Agentes citotoxicos que comprenden taxanos y su uso terapeutico. |
US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
WO2002024179A2 (en) * | 2000-09-22 | 2002-03-28 | Bristol-Myers Squibb Company | Method for reducing toxicity of combined chemotherapies |
WO2002049672A2 (en) * | 2000-12-21 | 2002-06-27 | Mcgill University | Conjugates of antibodies and anticancer drugs |
US20030003114A1 (en) * | 2001-03-22 | 2003-01-02 | Pan Xing Qing | Enzyme-based anti-cancer compositions and methods |
US7589180B2 (en) | 2001-05-11 | 2009-09-15 | Abbott Laboratories Inc. | Specific binding proteins and uses thereof |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
US7514078B2 (en) * | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
US7666414B2 (en) * | 2001-06-01 | 2010-02-23 | Cornell Research Foundation, Inc. | Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen |
MXPA03010804A (es) * | 2001-06-01 | 2004-11-22 | Cornell Res Foundation Inc | Anticuerpos modificados para antigeno de membrana especifico de la prostata y usos de los mismos. |
US6596757B1 (en) * | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
EP1552002A4 (de) * | 2002-06-18 | 2006-02-08 | Archemix Corp | Aptamer-toxinmoleküle sowie verfahren zu deren verwendung |
AU2003247762B2 (en) * | 2002-07-03 | 2008-05-01 | Immunogen, Inc. | Antibodies to non-shed MUC1 and MUC16, and uses thereof |
WO2004013093A2 (en) | 2002-08-02 | 2004-02-12 | Immunogen, Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
US7390898B2 (en) * | 2002-08-02 | 2008-06-24 | Immunogen Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
AU2003259163B2 (en) * | 2002-08-16 | 2008-07-03 | Immunogen, Inc. | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
EA009285B1 (ru) | 2003-05-14 | 2007-12-28 | Иммуноджен, Инк. | Композиция конъюгированного лекарственного средства |
MXPA06000830A (es) * | 2003-07-21 | 2006-04-18 | Immunogen Inc | Un conjugado citotoxico ca6 antigeno-especifico y metodos para utilizar el mismo. |
US7834155B2 (en) | 2003-07-21 | 2010-11-16 | Immunogen Inc. | CA6 antigen-specific cytotoxic conjugate and methods of using the same |
US7282590B2 (en) * | 2004-02-12 | 2007-10-16 | The Research Foundation Of State University Of New York | Drug conjugates |
EP1610818A4 (de) * | 2004-03-03 | 2007-09-19 | Millennium Pharm Inc | Modifizierte antikörper gegen ein prostataspezifisches membranantigen und verwendung dafür |
US7541330B2 (en) * | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
US8288557B2 (en) | 2004-07-23 | 2012-10-16 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
US20060045877A1 (en) * | 2004-08-30 | 2006-03-02 | Goldmakher Viktor S | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
EP1669358A1 (de) * | 2004-12-07 | 2006-06-14 | Aventis Pharma S.A. | Cytotoxische Wirkstoffen auf Basis von neuen Taxanen |
EP1688415A1 (de) | 2004-12-07 | 2006-08-09 | Aventis Pharma S.A. | Cytotoxische Wirkstoffe auf Basis von C2-modifizierten Taxanen |
CA2597407C (en) * | 2005-02-11 | 2013-09-10 | Immunogen, Inc. | Process for preparing stable drug conjugates |
US20110166319A1 (en) * | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
WO2006104677A2 (en) | 2005-03-24 | 2006-10-05 | Millennium Pharmaceuticals, Inc. | Antibodies that bind ov064 and methods of use therefor |
NZ623901A (en) | 2005-08-03 | 2015-10-30 | Immunogen Inc | Immunoconjugate formulations |
KR20130113543A (ko) * | 2005-08-19 | 2013-10-15 | 엔도사이트, 인코포레이티드 | 복수-약제 리간드 공액체 |
AU2006283726C1 (en) | 2005-08-24 | 2015-05-07 | Immunogen, Inc. | Process for preparing maytansinoid antibody conjugates |
EP1806365A1 (de) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antikörper spezifisch für Fibroblasten-Aktivierungsprotein und Immunokonjugaten, die diese Antikörper enthalten |
ATE527262T1 (de) | 2006-01-25 | 2011-10-15 | Sanofi Sa | Neue tomaymycin derivate enhaltende zytotoxische mittel |
CN101622276B (zh) * | 2006-07-18 | 2015-04-22 | 赛诺菲-安万特 | 用于治疗癌症的抗epha2的拮抗抗体 |
EP1914242A1 (de) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Neue Antikörper gegen CD38 zur Behandlung von Krebs |
EP3156415A1 (de) | 2006-11-22 | 2017-04-19 | Bristol-Myers Squibb Company | Gezielte therapeutik auf grundlage manipulierter proteine für tyrosinkinaserezeptoren, einschliesslich igf-ir |
WO2008091701A2 (en) * | 2007-01-25 | 2008-07-31 | Dana-Farber Cancer Institute | Use of anti-egfr antibodies in treatment of egfr mutant mediated disease |
EP2111228B1 (de) | 2007-02-02 | 2011-07-20 | Bristol-Myers Squibb Company | 10Fn3 Domain zur Behandlung von Krankheiten begleitet von unerwünschter Angiogenese |
US20080184892A1 (en) | 2007-02-06 | 2008-08-07 | Ctp Hydrogen Corporation | Architectures for electrochemical systems |
WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
JP5829793B2 (ja) | 2007-03-14 | 2015-12-09 | エンドサイト・インコーポレイテッドEndocyte, Inc. | 結合性リガンドが結合したツブリシンの薬剤送達結合体 |
WO2008115404A1 (en) * | 2007-03-15 | 2008-09-25 | Ludwing Institute For Cancer Research | Treatment method using egfr antibodies and src inhibitors and related formulations |
EP2139469A4 (de) * | 2007-03-19 | 2011-09-07 | Inflabloc Pharmaceuticals Inc | Cobalamintaxan-biokonjugate |
WO2009002993A1 (en) | 2007-06-25 | 2008-12-31 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
PL2019104T3 (pl) * | 2007-07-19 | 2014-03-31 | Sanofi Sa | Środki cytotoksyczne obejmujące nowe pochodne tomaymycyny i ich zastosowanie terapeutyczne |
PE20140196A1 (es) | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
CA2696360C (en) | 2007-08-14 | 2018-11-20 | Ludwig Institute For Cancer Research | Monoclonal antibody targeting the egfr receptor and uses thereof |
CA2700410C (en) * | 2007-10-03 | 2020-10-06 | Cornell University | Treatment of proliferative disorders using antibodies to psma |
MX2010007101A (es) * | 2007-12-26 | 2011-07-01 | Biotest Ag | Metodos y agentes para mejorar el reconocimiento de celulas de tumor que expresan cd138. |
HUE024291T2 (en) * | 2007-12-26 | 2016-01-28 | Biotest Ag | Immunoconjugates and Applications for CD138 |
JP2011507933A (ja) * | 2007-12-26 | 2011-03-10 | バイオテスト・アクチエンゲゼルシヤフト | 免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法 |
ES2475201T3 (es) * | 2007-12-26 | 2014-07-10 | Biotest Ag | Agentes dirigidos contra CD138 y usos de los mismos |
EP2278963A4 (de) * | 2008-01-16 | 2014-09-17 | Anwar Rayan | Derivate von taxol und eng verwandte verbindungen |
ES2629405T3 (es) | 2008-03-18 | 2017-08-09 | Genentech, Inc. | Combinaciones de un conjugado de fármaco-anticuerpo anti-HER2 y docetaxel |
DK2281006T3 (da) | 2008-04-30 | 2017-11-06 | Immunogen Inc | Tværbindingsmidler og anvendelser deraf |
JP2011520961A (ja) | 2008-05-22 | 2011-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | 多価フィブロネクチンをベースとする足場ドメインタンパク質 |
KR101835033B1 (ko) | 2009-02-05 | 2018-03-08 | 이뮤노젠 아이엔씨 | 신규한 벤조디아제핀 유도체 |
ES2712732T3 (es) * | 2009-02-17 | 2019-05-14 | Cornell Res Foundation Inc | Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico |
KR20160103160A (ko) | 2009-05-13 | 2016-08-31 | 젠자임 코포레이션 | 항-인간 cd52 면역글루불린 |
CN104984360A (zh) | 2009-06-03 | 2015-10-21 | 伊缪诺金公司 | 轭合方法 |
US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
AR078470A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | Anticuerpos que se unen especificamente al receptor epha2 |
KR20120080611A (ko) | 2009-10-06 | 2012-07-17 | 이뮤노젠 아이엔씨 | 효능 있는 접합체 및 친수성 링커 |
TWI483736B (zh) | 2009-10-23 | 2015-05-11 | Millennium Pharm Inc | 抗-gcc抗體分子及其相關之組合物及方法 |
RU2573994C2 (ru) | 2010-02-10 | 2016-01-27 | Иммьюноджен, Инк | Антитела против cd20 и их применение |
SG183847A1 (en) | 2010-03-04 | 2012-10-30 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
EP2552959B1 (de) | 2010-03-26 | 2017-01-11 | Memorial Sloan-Kettering Cancer Center | Antikörper gegen muc16 und anwendungsverfahren dafür |
US9133239B2 (en) | 2010-04-20 | 2015-09-15 | The Research Foundation For The State University Of New York | Compositions and methods for inhibiting matrix metalloproteinase (MMP)-mediated cell migration |
CN103298489A (zh) | 2010-10-29 | 2013-09-11 | 伊缪诺金公司 | 新型egfr结合分子及其免疫偶联物 |
CN105399831A (zh) | 2010-10-29 | 2016-03-16 | 伊缪诺金公司 | 非拮抗性egfr结合分子及其免疫偶联物 |
WO2012075173A2 (en) | 2010-12-01 | 2012-06-07 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
EP2648510B1 (de) | 2010-12-09 | 2016-08-31 | ImmunoGen, Inc. | Verfahren zur herstellung von geladenen vernetzern |
WO2012106368A2 (en) | 2011-01-31 | 2012-08-09 | The Regents Of The University Of California | Methods for inhibiting prostate cancer |
CA2824864C (en) | 2011-02-15 | 2019-04-09 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
MY171008A (en) | 2011-03-29 | 2019-09-23 | Immunogen Inc | Preparation of maytansinoid antibody conjugates by a one-step process |
RS58367B1 (sr) | 2011-03-29 | 2019-03-29 | Immunogen Inc | Priprema konjugata antitela i majtanzinoida jednostepenim postupkom |
SG195072A1 (en) | 2011-05-21 | 2013-12-30 | Macrogenics Inc | Cd3-binding molecules capable of binding to human and non-human cd3 |
CN103747804B (zh) | 2011-06-10 | 2016-08-17 | 梅尔莎纳医疗公司 | 蛋白质-聚合物-药物共轭物 |
US9289512B2 (en) | 2011-06-21 | 2016-03-22 | Immunogen, Inc. | Maytansinoid derivatives with peptide linker and conjugates thereof |
EA027900B1 (ru) | 2011-09-22 | 2017-09-29 | Эмджен Инк. | Связывающие антиген cd27l белки |
SG11201402343SA (en) | 2011-11-21 | 2014-06-27 | Immunogen Inc | Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate |
CN104302324A (zh) | 2011-12-08 | 2015-01-21 | 生物测试股份公司 | 靶向cd138的免疫偶联物的用途 |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
EP2841099A1 (de) | 2012-04-26 | 2015-03-04 | Boehringer Ingelheim International GmbH | Kombination von cd37-antikörpern mit bendamustin |
WO2013171287A1 (en) | 2012-05-16 | 2013-11-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide) |
WO2013171289A1 (en) | 2012-05-16 | 2013-11-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with further agents |
UY34813A (es) | 2012-05-18 | 2013-11-29 | Amgen Inc | Proteínas de unión a antígeno dirigidas contra el receptor st2 |
US20150104468A1 (en) | 2012-06-04 | 2015-04-16 | Irm Llc | Site-specific labeling methods and molecules produced thereby |
SG10201702737TA (en) | 2012-10-04 | 2017-05-30 | Immunogen Inc | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
CA2887727A1 (en) | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
CA2891280C (en) | 2012-11-24 | 2018-03-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
WO2014093379A1 (en) | 2012-12-10 | 2014-06-19 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
WO2014093394A1 (en) | 2012-12-10 | 2014-06-19 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
US9872918B2 (en) | 2012-12-12 | 2018-01-23 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
ES2728936T3 (es) | 2013-01-25 | 2019-10-29 | Amgen Inc | Anticuerpos dirigidos contra CDH19 para melanoma |
WO2014124258A2 (en) | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
KR102447350B1 (ko) | 2013-02-08 | 2022-09-23 | 노파르티스 아게 | 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위 |
US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
AR095199A1 (es) | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
US9789203B2 (en) | 2013-03-15 | 2017-10-17 | Novartis Ag | cKIT antibody drug conjugates |
PL3004167T3 (pl) | 2013-05-30 | 2019-01-31 | Kiniksa Pharmaceuticals, Ltd. | Białka wiążące antygen receptora onkostatyny m |
TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
EP3054991B1 (de) | 2013-10-11 | 2019-04-03 | Mersana Therapeutics, Inc. | Protein-polymer-wirkstoffkonjugate |
KR102355745B1 (ko) | 2013-10-11 | 2022-01-26 | 아사나 바이오사이언시스 엘엘씨 | 단백질-폴리머-약물 접합체 |
US9943606B2 (en) | 2014-01-15 | 2018-04-17 | Rutgers, The State University Of New Jersey | Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents |
CN103804472B (zh) * | 2014-01-23 | 2016-06-08 | 浙江大学 | 一种紫杉烷类药物前体 |
US10100115B2 (en) | 2014-02-14 | 2018-10-16 | Macrogenics, Inc. | Methods for the treatment of vascularizing cancers |
ES2960619T3 (es) | 2014-02-28 | 2024-03-05 | Hangzhou Dac Biotech Co Ltd | Enlazadores cargados y sus usos para la conjugación |
EA201691827A1 (ru) | 2014-03-12 | 2017-01-30 | Новартис Аг | Конкретные участки для модификации антител с целью получения иммуноконъюгатов |
WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
KR20170040249A (ko) | 2014-08-12 | 2017-04-12 | 노파르티스 아게 | 항-cdh6 항체 약물 접합체 |
TW201613930A (en) | 2014-09-03 | 2016-04-16 | Immunogen Inc | Cytotoxic benzodiazepine derivatives |
TWI757759B (zh) | 2014-09-03 | 2022-03-11 | 美商免疫原公司 | 細胞毒性苯并二氮呯衍生物 |
GB201416960D0 (en) | 2014-09-25 | 2014-11-12 | Antikor Biopharma Ltd | Biological materials and uses thereof |
US10005836B2 (en) | 2014-11-14 | 2018-06-26 | Novartis Ag | Antibody drug conjugates |
CN114656483A (zh) | 2014-12-04 | 2022-06-24 | 细胞基因公司 | 生物分子共轭物 |
KR102618312B1 (ko) | 2015-03-17 | 2023-12-28 | 메모리얼 슬로안 케터링 캔서 센터 | 항muc16 항체 및 그의 용도 |
US10722523B2 (en) | 2015-03-17 | 2020-07-28 | The Regents Of The University Of California | Chemoimmunotherapy for epithelial cancer |
US10548989B2 (en) | 2015-04-07 | 2020-02-04 | Memorial Sloan Kettering Cancer Center | Nanoparticle immunoconjugates |
US20190194315A1 (en) | 2015-06-17 | 2019-06-27 | Novartis Ag | Antibody drug conjugates |
CA2988806A1 (en) | 2015-06-29 | 2017-01-05 | Immunogen, Inc. | Conjugates of cysteine engineered antibodies |
WO2015151081A2 (en) | 2015-07-12 | 2015-10-08 | Suzhou M-Conj Biotech Co., Ltd | Bridge linkers for conjugation of a cell-binding molecule |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
CN108026103B (zh) | 2015-07-21 | 2021-04-16 | 伊缪诺金公司 | 制备细胞毒性苯并二氮杂䓬衍生物的方法 |
WO2017025458A1 (en) | 2015-08-07 | 2017-02-16 | Gamamabs Pharma | Antibodies, antibody drug conjugates and methods of use |
JP2018535655A (ja) | 2015-09-29 | 2018-12-06 | アムジエン・インコーポレーテツド | Asgr阻害剤 |
RS65120B1 (sr) | 2015-11-25 | 2024-02-29 | Immunogen Inc | Farmaceutske formulacije i postupci za njihovu upotrebu |
TW201808336A (zh) | 2016-05-11 | 2018-03-16 | 賽諾菲公司 | 用抗muc1類美登素免疫綴合物抗體治療腫瘤的治療方案 |
KR102459468B1 (ko) | 2016-11-14 | 2022-10-26 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
WO2018098258A2 (en) | 2016-11-23 | 2018-05-31 | Immunogen, Inc. | Selective sulfonation of benzodiazepine derivatives |
US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
RU2022101392A (ru) | 2017-02-28 | 2022-03-02 | Иммуноджен, Инк. | Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты |
WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
TW201839001A (zh) | 2017-04-20 | 2018-11-01 | 美商伊繆諾金公司 | 細胞毒性苯并二氮平衍生物及其綴合物 |
WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
CN111315414A (zh) | 2017-06-22 | 2020-06-19 | 梅尔莎纳医疗公司 | 产生载药聚合物支架和蛋白-聚合物-药物缀合物的方法 |
EP4085919A3 (de) | 2017-07-21 | 2023-02-08 | Novartis AG | Zusammensetzungen und verfahren zur behandlung von krebs |
WO2019133652A1 (en) | 2017-12-28 | 2019-07-04 | Immunogen, Inc. | Benzodiazepine derivatives |
US11401336B2 (en) | 2018-02-21 | 2022-08-02 | Celgene Corporation | BCMA-binding antibodies and uses thereof |
US20210330802A1 (en) | 2018-10-10 | 2021-10-28 | Takeda Pharmaceutical Company Limited | Method for producing antibody-drug conjugate |
MX2021004906A (es) | 2018-10-29 | 2021-09-10 | Mersana Therapeutics Inc | Conjugados de anticuerpo modificado con cisteína-fármaco con enlazadores que contienen péptidos. |
WO2020089811A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody drug conjugates |
CN113195541A (zh) | 2018-12-21 | 2021-07-30 | 诺华股份有限公司 | 针对pmel17的抗体及其缀合物 |
KR20210154158A (ko) | 2019-03-20 | 2021-12-20 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 클라우딘-6 항체 및 약물 컨쥬게이트 |
CN113661172A (zh) | 2019-03-29 | 2021-11-16 | 伊缪诺金公司 | 用于抑制异常细胞生长或治疗增生性疾病的细胞毒性双苯并二氮杂䓬衍生物及其与细胞结合剂的缀合物 |
EP4316524A3 (de) | 2019-04-26 | 2024-04-24 | ImmunoGen, Inc. | Camptothecinderivate |
EP4087614A1 (de) | 2020-01-09 | 2022-11-16 | Mersana Therapeutics, Inc. | Ortsspezifische antikörper-wirkstoff-konjugate mit peptidhaltigen linkern |
KR20230004453A (ko) | 2020-02-25 | 2023-01-06 | 메디보스턴 리미티드 | 캄프토테신 유도체 및 이의 접합체 |
US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
US20230256114A1 (en) | 2020-07-07 | 2023-08-17 | Bionecure Therapeutics, Inc. | Novel maytansinoids as adc payloads and their use for the treatment of cancer |
EP3970752A1 (de) | 2020-09-17 | 2022-03-23 | Merck Patent GmbH | Moleküle mit löslichkeitsmarkierung und zugehörige verfahren |
MX2023006010A (es) | 2020-11-24 | 2023-06-08 | Novartis Ag | Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos. |
US20220378929A1 (en) | 2021-02-25 | 2022-12-01 | MediBoston Limted | Anti-her2 antibody-drug conjugates and uses thereof |
WO2022221720A1 (en) | 2021-04-16 | 2022-10-20 | Novartis Ag | Antibody drug conjugates and methods for making thereof |
US20240108744A1 (en) | 2022-07-27 | 2024-04-04 | Mediboston Limited | Auristatin derivatives and conjugates thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE120454T1 (de) * | 1988-06-14 | 1995-04-15 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5399726A (en) * | 1993-01-29 | 1995-03-21 | Florida State University | Process for the preparation of baccatin III analogs bearing new C2 and C4 functional groups |
ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
US5646176A (en) * | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
US5475011A (en) | 1993-03-26 | 1995-12-12 | The Research Foundation Of State University Of New York | Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment |
US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5824701A (en) * | 1993-10-20 | 1998-10-20 | Enzon, Inc. | Taxane-based prodrugs |
US5663199A (en) * | 1994-11-30 | 1997-09-02 | Uniroyal Chemical Ltd./Ltee | Anti-viral aromatic O-alkylated oximes, ethers and thioethers |
WO1997044026A1 (en) * | 1996-05-22 | 1997-11-27 | Neuromedica, Inc. | Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere |
EP0941120A4 (de) | 1996-11-05 | 2004-08-18 | Bristol Myers Squibb Co | Verzweigte peptidlinker |
US5811452A (en) | 1997-01-08 | 1998-09-22 | The Research Foundation Of State University Of New York | Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof |
ES2210761T3 (es) * | 1997-05-21 | 2004-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas. |
US6545125B1 (en) * | 1997-11-18 | 2003-04-08 | Chugai Seiyaku Kabushiki Kaisha | Compounds with antitumor activity |
JP4808846B2 (ja) | 1999-02-24 | 2011-11-02 | ザ ユーエイビー リサーチ ファンデイション | 癌の標的付けられた治療のためのタキサン誘導体 |
ES2276708T3 (es) * | 1999-11-24 | 2007-07-01 | Immunogen, Inc. | Agentes citotoxicos que comprenden taxanos y su uso terapeutico. |
US6175023B1 (en) * | 2000-01-31 | 2001-01-16 | Jian Liu | Synthesis of water soluble 9-dihydro-paclitaxel derivatives from 9-dihydro-13-acetylbaccatin III |
-
2000
- 2000-11-21 ES ES00982077T patent/ES2276708T3/es not_active Expired - Lifetime
- 2000-11-21 PT PT00982077T patent/PT1242401E/pt unknown
- 2000-11-21 DK DK00982077T patent/DK1242401T3/da active
- 2000-11-21 AT AT00982077T patent/ATE349438T1/de active
- 2000-11-21 AU AU19149/01A patent/AU765588C/en not_active Ceased
- 2000-11-21 WO PCT/US2000/030149 patent/WO2001038318A1/en active IP Right Grant
- 2000-11-21 DE DE60032633T patent/DE60032633T2/de not_active Expired - Lifetime
- 2000-11-21 NZ NZ517772A patent/NZ517772A/xx unknown
- 2000-11-21 CA CA2388063A patent/CA2388063C/en not_active Expired - Fee Related
- 2000-11-21 EP EP00982077A patent/EP1242401B1/de not_active Expired - Lifetime
- 2000-11-21 JP JP2001540081A patent/JP2003514903A/ja active Pending
- 2000-11-22 US US09/717,026 patent/US6340701B1/en not_active Expired - Fee Related
-
2001
- 2001-08-21 US US09/933,018 patent/US6372738B2/en not_active Expired - Fee Related
-
2002
- 2002-01-30 US US10/059,022 patent/US6436931B1/en not_active Expired - Fee Related
- 2002-07-31 US US10/207,814 patent/US6706708B2/en not_active Expired - Fee Related
-
2003
- 2003-03-11 HK HK03101738.2A patent/HK1049997B/zh not_active IP Right Cessation
- 2003-10-15 US US10/684,746 patent/US7008942B2/en not_active Expired - Fee Related
-
2005
- 2005-08-16 US US11/203,960 patent/US7217819B2/en not_active Expired - Fee Related
-
2006
- 2006-01-06 US US11/326,504 patent/US7528130B2/en not_active Expired - Fee Related
- 2006-01-13 US US11/331,045 patent/US7276499B2/en not_active Expired - Fee Related
-
2007
- 2007-04-18 US US11/785,483 patent/US7550609B2/en not_active Expired - Fee Related
- 2007-04-18 US US11/785,482 patent/US7476669B2/en not_active Expired - Fee Related
- 2007-08-23 US US11/844,183 patent/US7585857B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60032633D1 (de) | Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung | |
ATE344801T1 (de) | Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung | |
WO2004013093A3 (en) | Cytotoxic agents containing novel potent taxanes and their therapeutic use | |
ECSP055635A (es) | Agentes citotoxicos que contienen taxanos potentes novedosos y su uso terapeutico | |
DE69028678T2 (de) | Maytansinoid enthaltende cytotoxische Mittel und ihre therapeutische Anwendung | |
WO2003068144A3 (en) | Cytotoxic agents | |
YU37301A (sh) | Farmaceutski preparat za modifikovano oslobađanje sensitizera insulina i drugog antidijabetskog agensa | |
WO2003061577A3 (en) | Polyalkylene glycol with moiety for conjugating biologically active compound | |
DK0740650T3 (da) | Codrugs som metode til styret transport af lægemiddel | |
EP2266607A3 (de) | Immunokonjugate für Krebsbehandlung | |
PT1411118E (pt) | Inibidores da proliferação celular contendo um anticorpo anti-glipicano 3 | |
RU2011115418A (ru) | Усиление действия противораковых агентов | |
DE60021059D1 (de) | Hydrogelpartikel formulierungen | |
CA2212537A1 (en) | Therapeutic inhibitor of vascular smooth muscle cells | |
BRPI0416028A (pt) | composto, conjugados do composto e de anticorpo-medicamento, composições farmacêuticas, usos dos conjugados, métodos para tratamento de cáncer, de uma doença auto-imune, de uma doença infecciosa e de um paciente, método para inibir a proliferação ou matar as células de tumor ou células cancerìgenas, método de inibição do crescimento de células de tumor, análise para detectar células de cáncer e artigo de manufatura | |
BR0309278A (pt) | Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto | |
HK1075205A1 (en) | Combination of selected opioids with muscarine antagonists for treating urinary incontinence | |
AR003427A1 (es) | Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas. | |
WO2002026191A3 (en) | Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue | |
CA2384418C (en) | Use of cytokines, cells, and mitogens to inhibit graft versus host disease | |
ATE206059T1 (de) | Heparin-beschichtete medizinische geräte zum intravenösen gebrauch, die heparin-bindende wachstumfaktor-konjugate enthalten | |
ATE210978T1 (de) | Pharmazeutische zusammensetzung enthaltend uscharin | |
HK1044795A1 (en) | Pharmaceutical composition comprising pim-activated nkt cells, and therapeutic use thereof | |
AR010343A1 (es) | Uso de 17 beta-dihidroequilenina o una sal farmaceuticamente aceptable del ester de 17 beta-dihidroequilenina-3-sulfato para la manufactura de unmedicamento como antioxidante y composicion farmaceutica. | |
ATE329613T1 (de) | Wachstumhormone inhibitoren enthaltende pharmazeutische zubereitungen oder ihre biologisch aktive fragmente zur behandlung von uterinen myomas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |